Adults Age 60 and Older in Georgia, Maryland and Texas Encouraged to Join Clinical Trial for RSV Prevention Vaccine
Each year in the U.S., more than 177,000 individuals who are age 65 or over are hospitalized due to RSV, and approximately 14,000 of them die from the virus.1 Furthermore, the treatment of RSV in older adults generates an estimated $3 billion in annual medical costs nationally. Due to these concerns, preventing RSV in older adults is urgently important to public health, yet there is no approved preventive vaccine available.
We are currently recruiting for a clinical trial RSV vaccine. This clinical trial is a new investigational vaccine designed to protect older adults from the respiratory syncytial virus (RSV). This clinical trial is being launched in partnership with certain Privia Health Group (Nasdaq: PRVA) subsidiaries and affiliates.
Eligible participants for this study must:
- Be 60 years of age or older
- Be healthy and willing to attend all scheduled visits
- Be willing to comply with all study visits and requirements
This study may provide compensation for your time and travel. Transportation to and from clinical research visits can be made available to you at no cost. Compensation for time and travel may also be provided.
1. Older Adults Are at High Risk for Severe RSV Infection. Centers for Disease Control website. https://www.cdc.gov/rsv/factsheet-older-adults.pdf. Published August 2017. Accessed Nov. 3, 2021.